Biotech Growth Trust plc (The) (BIOG) Ordinary 25p

- Add to watchlist
- Create an alert
- This stock can be held in a




734.00p
746.00p
1,068.00p
814.57
738.00p
732.00p
616.00p
-9.40%
2.00p (0.27%) Previous:
2.00p
97,949
n/a
GBX
Price
-
Net Asset Value (NAV)
Performance
1 week 1W | 2.76% | 1 year 1Y | 22.98% |
---|---|---|---|
1 month 1M | 3.38% | 2 years 2Y | 14.19% |
3 months 3M | 6.53% | 3 years 3Y | 7.12% |
6 months 6M | 20.85% | 5 years 5Y | 34.51% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | NASDAQ Biotechnology TR GBP |
---|---|
Annual management charge: | n/a |
Performance fee: | Yes |
Ongoing charge: | 1.20% |
Dividend yield: | n/a |
Dividend frequency: | None |
Total assets: | £214m |
Gross gearing: | 0% |
Market capitalisation:Market cap.: | £194m |
Shares in issue: | 26.23 million |
Legal structure | Closed Ended Investment Company |
Domicile: | United Kingdom |
ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | 814.57p |
---|---|
Latest actual NAV: | 817.11p |
Latest actual NAV date: | 4 June 2025 |
Premium/Discount: | -9.40% |
12m average Premium/Discount: | -8.41% |
NAV frequency: | Daily |
Security | Weight |
---|---|
Gilead Sciences Inc | 12.69% |
Sarepta Therapeutics Inc | 6.04% |
Neurocrine Biosciences Inc | 4.97% |
Argen X SE EUR0.10 | 4.89% |
Amgen Inc | 4.18% |
Avidity Biosciences Inc Ordinary Shares | 3.85% |
Xenon Pharmaceuticals Inc | 3.63% |
Cytokinetics Inc | 3.46% |
Amicus Therapeutics Inc | 3.35% |
Alnylam Pharmaceuticals Inc | 3.32% |
Sector | Weight |
---|---|
Healthcare | 98.62% |
Country | Weight |
---|---|
United States | 88.76% |
Canada | 4.60% |
China | 4.39% |
Switzerland | 1.15% |
Germany | 0.97% |
Key Dates
Launch date: | 23 June 1997 |
---|---|
Financial year end: | March |
Next AGM: | July 2025 |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.